MX2016001032A - Metodos y composiciones que comprenden desmopresina en combinacion con un inhibidor de 5-alfa reductasa. - Google Patents
Metodos y composiciones que comprenden desmopresina en combinacion con un inhibidor de 5-alfa reductasa.Info
- Publication number
- MX2016001032A MX2016001032A MX2016001032A MX2016001032A MX2016001032A MX 2016001032 A MX2016001032 A MX 2016001032A MX 2016001032 A MX2016001032 A MX 2016001032A MX 2016001032 A MX2016001032 A MX 2016001032A MX 2016001032 A MX2016001032 A MX 2016001032A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- methods
- desmopressin
- combination
- reductase inhibitor
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 229940113178 5 Alpha reductase inhibitor Drugs 0.000 title abstract 2
- 239000002677 5-alpha reductase inhibitor Substances 0.000 title abstract 2
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 title abstract 2
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 title abstract 2
- 229960004281 desmopressin Drugs 0.000 title abstract 2
- 206010036018 Pollakiuria Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 206010029446 nocturia Diseases 0.000 abstract 1
- 208000022934 urinary frequency Diseases 0.000 abstract 1
- 230000036318 urination frequency Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La invención brinda métodos y composiciones para uso de desmopresina en combinación con un inhibidor de 5-alfa reductasa. Los métodos y composiciones son útiles en el tratamiento de nicturia y otros trastornos de frecuencia urinaria.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361857428P | 2013-07-23 | 2013-07-23 | |
PCT/US2014/047897 WO2015013453A1 (en) | 2013-07-23 | 2014-07-23 | Methods and compositions comprising desmopressin in combination with a 5-alpha reductase inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016001032A true MX2016001032A (es) | 2017-10-31 |
Family
ID=51299054
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016001032A MX2016001032A (es) | 2013-07-23 | 2014-07-23 | Metodos y composiciones que comprenden desmopresina en combinacion con un inhibidor de 5-alfa reductasa. |
Country Status (9)
Country | Link |
---|---|
US (1) | US9925232B2 (es) |
EP (1) | EP3024473A1 (es) |
JP (3) | JP2016525147A (es) |
KR (3) | KR20210103590A (es) |
CN (1) | CN105579056A (es) |
AU (1) | AU2014293140A1 (es) |
CA (1) | CA2919194A1 (es) |
MX (1) | MX2016001032A (es) |
WO (1) | WO2015013453A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20240015735A (ko) | 2013-07-23 | 2024-02-05 | 세레니티 파마슈티컬즈 엘엘씨 | 베타-3-아드레날린 수용체 작용제와 함께 데스모프레신을 포함하는 방법 및 조성물 |
KR20240010751A (ko) * | 2014-11-20 | 2024-01-24 | 세레니티 파마슈티컬즈 엘엘씨 | 알파-아드레날린성 수용체 길항제와 조합된 데스모프레신을 포함하는 방법 및 조성물 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH495957A (de) | 1966-09-15 | 1970-09-15 | Ceskoslovenska Akademie Ved | Verfahren zur Herstellung eines antidiuretisch wirksamen Polypeptids |
US3989816A (en) | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
US4316893A (en) | 1975-06-19 | 1982-02-23 | Nelson Research & Development Co. | Vehicle composition containing 1-substituted azacycloalkan-2-ones |
US4505616A (en) | 1983-05-26 | 1985-03-19 | Litton Systems, Inc. | Self-locking chock system for a jack-up rig unit |
US4557934A (en) | 1983-06-21 | 1985-12-10 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US4783450A (en) | 1987-04-13 | 1988-11-08 | Warner-Lambert Company | Use of commercial lecithin as skin penetration enhancer |
NZ241979A (en) * | 1991-03-20 | 1996-01-26 | Merck & Co Inc | Treatment of benign prostatic hyperplasia using 5alpha-reductase inhibitor and an alpha1-adrenergic recepter blocker |
US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
US7335186B2 (en) | 1998-03-13 | 2008-02-26 | Alexander George Brian O'Neil | Patient controlled drug delivery device |
US6558695B2 (en) | 1999-12-16 | 2003-05-06 | Dermatrends, Inc. | Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers |
US7244703B2 (en) | 2001-06-22 | 2007-07-17 | Bentley Pharmaceuticals, Inc. | Pharmaceutical compositions and methods for peptide treatment |
GB0210397D0 (en) * | 2002-05-07 | 2002-06-12 | Ferring Bv | Pharmaceutical formulations |
US6945952B2 (en) | 2002-06-25 | 2005-09-20 | Theraject, Inc. | Solid solution perforator for drug delivery and other applications |
EP2322195A2 (en) * | 2003-11-10 | 2011-05-18 | Reprise Biopharmaceutics, LLC | Pharmaceutical compositions including low dosages of desmopressin |
ES2348303T3 (es) | 2003-12-08 | 2010-12-02 | Cpex Pharmaceuticals, Inc. | Composiciones farmacauticas y procedimientos de tratamiento con insulina. |
CA2633570A1 (en) * | 2005-12-21 | 2007-06-28 | Pfizer Products Inc. | Pharmaceutical combination of a pde-5 inhibitor and a 5-alpha reductase inhibitor |
CA2988753A1 (en) | 2007-08-06 | 2009-02-12 | Serenity Pharmaceuticals, Llc | Methods and devices for desmopressin drug delivery |
US20100160214A1 (en) | 2008-12-22 | 2010-06-24 | Serenity Pharmaceuticals Corporation | Desmopressin composition |
MX2011006765A (es) | 2008-12-22 | 2011-11-01 | Allergan Inc | Administracion intranasal de desmopresina. |
PL4104848T3 (pl) | 2009-06-18 | 2024-03-25 | Acerus Pharmaceuticals USA, LLC | Bezpieczne podawanie desmopresyny |
KR20240015735A (ko) | 2013-07-23 | 2024-02-05 | 세레니티 파마슈티컬즈 엘엘씨 | 베타-3-아드레날린 수용체 작용제와 함께 데스모프레신을 포함하는 방법 및 조성물 |
-
2014
- 2014-07-23 CA CA2919194A patent/CA2919194A1/en active Pending
- 2014-07-23 JP JP2016529871A patent/JP2016525147A/ja active Pending
- 2014-07-23 KR KR1020217025794A patent/KR20210103590A/ko active Application Filing
- 2014-07-23 MX MX2016001032A patent/MX2016001032A/es unknown
- 2014-07-23 WO PCT/US2014/047897 patent/WO2015013453A1/en active Application Filing
- 2014-07-23 KR KR1020247002754A patent/KR20240015736A/ko active Application Filing
- 2014-07-23 AU AU2014293140A patent/AU2014293140A1/en not_active Abandoned
- 2014-07-23 US US14/338,567 patent/US9925232B2/en active Active
- 2014-07-23 EP EP14748449.7A patent/EP3024473A1/en not_active Withdrawn
- 2014-07-23 CN CN201480052300.2A patent/CN105579056A/zh active Pending
- 2014-07-23 KR KR1020167004345A patent/KR20160034366A/ko not_active Application Discontinuation
-
2020
- 2020-04-01 JP JP2020065914A patent/JP2020114858A/ja active Pending
-
2022
- 2022-07-15 JP JP2022114040A patent/JP2022137252A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20160034366A (ko) | 2016-03-29 |
WO2015013453A1 (en) | 2015-01-29 |
JP2016525147A (ja) | 2016-08-22 |
CA2919194A1 (en) | 2015-01-29 |
CN105579056A (zh) | 2016-05-11 |
JP2020114858A (ja) | 2020-07-30 |
KR20240015736A (ko) | 2024-02-05 |
AU2014293140A1 (en) | 2016-03-03 |
KR20210103590A (ko) | 2021-08-23 |
US20150031614A1 (en) | 2015-01-29 |
US9925232B2 (en) | 2018-03-27 |
EP3024473A1 (en) | 2016-06-01 |
JP2022137252A (ja) | 2022-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20190270T1 (hr) | C1-inh pripravci i postupci za prevenciju i liječenje poremećaja povezanih s nedostatkom inhibitora c1 esteraze | |
HK1224140A1 (zh) | 轉錄因子抑制劑及其用途 | |
HK1223089A1 (zh) | 激酶抑制劑及其用途 | |
HK1219421A1 (zh) | 激酶抑制劑的組合及其用途 | |
MX369691B (es) | Inhibidores de glutaminasa y métodos de empleo. | |
MX2013015311A (es) | Polipeptidos de enlace de pcsk9 y metodos de uso. | |
HK1217896A1 (zh) | 用於治療廣泛性發展障礙的複合物及方法 | |
MX2016001030A (es) | Métodos y composiciones que comprenden desmopresina en combinación con un agonista del receptor beta 3-adrenérgico. | |
MX2017006019A (es) | Apilimod para uso en el tratamiento de melanoma. | |
IL240553B (en) | il-1ß inhibitory compounds and use thereof | |
HUE046190T2 (hu) | GATA-3 inhibitorok TH2-vezérelt asztma kezelése során történõ alkalmazásra | |
EP2964225A4 (en) | CAMKII INHIBITORS AND USES THEREOF | |
MX2016001032A (es) | Metodos y composiciones que comprenden desmopresina en combinacion con un inhibidor de 5-alfa reductasa. | |
GEP201706795B (en) | Hexahydrofuropyrroles as pde1 inhibitors | |
PL3024825T3 (pl) | Imidazolokarboksyamidy i ich zastosowanie jako inhibitorów faah | |
MX2017006655A (es) | Metodos y composiciones que comprenden desmopresina en combinacion con un antagonista del receptor alfa-adrenergico. | |
MX2015014063A (es) | Composicion anti tumoral que comprende un inhibidor selectivo pi3kbeta y un inhibidor selectivo pi3kalfa. | |
GB201321353D0 (en) | Transformer tapping arrangement and methods of operation of same | |
MY168958A (en) | Intermediates and processes for preparing compounds |